BRAVELLE® is a highly purified preparation of human follicle FSH, containing 75 IUs FSH with 2% luteinizing hormone (LH) activity. BRAVELLE® stimulates eggs to mature in women whose ovaries are basically healthy but are unable to develop eggs. It is not used by women who suffer from ovarian failure.

BRAVELLE® is usually used together with human chorionic gonadotropin (hCG), and is indicated for ovulation induction following pituitary suppression and multiple follicular development following pituitary suppression.

In Assisted Reproductive Technology (ART), BRAVELLE® is unique in that it is the only FSH designed to be a partner to hMG. Widely studied for safety and effectiveness in mixed protocol, patients can mix hMG and BRAVELLE® in 1 syringe and administer 1 injection a day1. Only BRAVELLE® demonstrates efficacy across a wide range of patient types (younger patients3, older patients4, donor oocyte patients5, elevated body mass index (BMI) patients6).

BRAVELLE® is available by prescription in 5mL vials containing 75 IU FSH with accompanying diluent.